Sidestepping maternal antibody: A lesson from measles virus vaccination

Expert Review of Clinical Immunology

Volumn 7, Issue 5, 2011, Pages 557-559

  Kim, Dhohyung ^a   Niewiesk, Stefan ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

B cell activation; CD32; complement receptor 2; inhibition of seroconversion; maternal antibodies; measles virus; neutralizing antibodies; regulatory mechanism of IgG; type I interferon

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD40 LIGAND; EPITOPE; FC RECEPTOR IIB; HEMAGGLUTININ; IMMUNOGLOBULIN G; MATERNAL ANTIBODY; MEASLES ANTIBODY; MEASLES VACCINE; NEUTRALIZING ANTIBODY;

ANTIBODY RESPONSE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL INTERACTION; CROSS LINKING; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEEDBACK SYSTEM; HUMAN; IMMUNIZATION; NONHUMAN; PASSIVE TRANSPORT; REVIEW; T LYMPHOCYTE;

ANTIBODIES, VIRAL; FEMALE; HUMANS; MALE; MATERNAL-FETAL EXCHANGE; MEASLES; MEASLES VACCINE; MEASLES VIRUS; PREGNANCY; VACCINATION;

EID: 80052637031     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.11.48     Document Type: Review

References (18)

1. GriffDE, Pan C-H. Measles: old vaccines and new vaccines. In:Measles - Pathogenesis and Control. Griffin DE, Oldstone MBA (Eds).Springer Verlag, Heidelberg, Germany, 191-212 (2009).
2. Gans H, Yasukawa L, Rinki M et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J. Infect. Dis. 184, 817-826 (2001). (Pubitemid 32881086)
3. 8+ lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J. Virol. 77, 4396-4400 (2003). (Pubitemid 36350977)
4. Pueschel K, Tietz A, Carsillo M, Steward M, Niewiesk S. Measles virus-specific CD4 T-cell activity does not correlate with protection against lung infection or viral clearance. J. Virol. 81(16), 8571-8578 (2007). (Pubitemid 47242830)
5. Katz M. Clinical spectrum of measles. In:Measles Virus. Billeter M, ter Meulen V (Eds).Springer, Berlin, Germany, 1-12 (1995).
6. Aaby P, Jensen T, Hansen H. Trial of high dose Edmonston-Zagreb measles vaccine in Guinea-Bissau: protective efficacy. Lancet 2, 809-811 (1988).
7. Whittle H, Hanlon P, O'Neil K, Hanlon L, Marsh V, Jupp E. Trial of high-dose Edmonston-Zagreb measles vaccine in Gambia: antibody response and side-effects. Lancet 2, 811-814 (1988).
8. Garenne M, Leroy O, Beau J, Sene I. Child mortality after high titer measles vaccine: prospective study in Senegal. Lancet 338, 903-907 (1991).
9. Halsey N. Increased mortality following high titer measles vaccines: too much of a good thing. J. Pediatr. Infect. Dis. 12, 462-465 (1993). (Pubitemid 23173488)
10. Seng R, Samb B, Simondon F et al. Increased long term mortality associated with rash after early measles vaccination in rural Senegal. Pediatr. Infect. Dis. J. 18, 48-52 (1999). (Pubitemid 29055269)
11. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. J. Am. Med. Assoc. 280, 527-532 (1998). (Pubitemid 28377671)
12. Johnson CE, Darbari A, Darbari DS et al. Measles vaccine immunogenicity and antibody persistence in 12 vs 15-month old infants. Vaccine 18, 2411-2415 (2000). (Pubitemid 30156812)
13. Gans H, DeHovitz R, Forghani B, Beeler J, Maldonado Y, Arvin AM. Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine 21, 3398-3405 (2003). (Pubitemid 36792094)
14. Siegrist C. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 21, 3406-3412 (2003). (Pubitemid 36798059)
15. Heyman B. Functions of antibodies in the regulation of B cell responses in vivo. Springer Semin. Immunopathol. 23, 421-432 (2001). (Pubitemid 34045279)
16. Niewiesk S. Current animal models: cotton rat. In:Measles - Pathogenesis and Control. Griffin DE, Oldstone MBA (Eds).Springer Verlag, Heidelberg, Germany, 89-110 (2009).
17. Kim D, Huey D, Oglesbee M, Niewiesk S. Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies. Blood 117, 6143-6151 (2011).
18. Kim D, Maritinez-Sobrido L, Choi C et al. Induction of type I interferon secretion through recombinant Newcastle disease virus expressing measles virus hemagglutinin stimulates antibody secretion in the presence of maternal antibodies. J. Virol. 85, 200-207 (2011).